|
|
Volumn 20, Issue 3, 2002, Pages 727-731
|
|
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DOCETAXEL;
DOXORUBICIN;
IMMUNOLOGIC AGENT;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
UNCLASSIFIED DRUG;
ADULT;
ARTICLE;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER RISK;
CANCER STAGING;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
DRUG SAFETY;
DRUG TOLERABILITY;
FEBRILE NEUTROPENIA;
FEMALE;
HUMAN;
LEUKOCYTE COUNT;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
NEUTROPENIA;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
DELAYED-ACTION PREPARATIONS;
DOUBLE-BLIND METHOD;
DOXORUBICIN;
FEMALE;
FILGRASTIM;
HUMANS;
INJECTIONS, SUBCUTANEOUS;
MALE;
MIDDLE AGED;
NEOPLASM STAGING;
NEUTROPENIA;
PACLITAXEL;
TAXOIDS;
|
|
EID: 0036467835
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.20.3.727 Document Type: Article |
|
Times cited : (521)
|
|
References (12)
|
